The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The association between prior exposure to lenalidomide and TP53-mutated AML/MDS
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the results of a study investigating the relationship between the genetics of therapy-related myeloid neoplasms and prior chemotherapy exposure. The study showed that prior lenalidomide exposure was associated with TP53-mutated acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Experiments on animal models showed that this was due to lenalidomide-induced casein kinase degradation. Therefore, using lenalidomide analogs such as thalidomide or iberdomide that do not degrade casein kinase could represent a safer treatment option in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
